Vanguard Group
AIM

Vanguard Group’s AIM ImmunoTech AIM Stock Holding History

Vanguard Group’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$19.8K Hold
17,520
– – ﹤0.01% 4308
2025
Q3 		$48K Buy
+17,520
New +$78.4K ﹤0.01% 4303
2025
Q2 		– Sell
-24,468
Closed -$298K – 4382
2025
Q1 		$298K Buy
24,468
+4,561
+23% +$73.3K ﹤0.01% 3994
2024
Q4 		$394K Hold
19,907
– – ﹤0.01% 3994
2024
Q3 		$537K Hold
19,907
– – ﹤0.01% 3957
2024
Q2 		$741K Hold
19,907
– – ﹤0.01% 3888
2024
Q1 		$937K Hold
19,907
– – ﹤0.01% 3838
2023
Q4 		$875K Hold
19,907
– – ﹤0.01% 3875
2023
Q3 		$905K Hold
19,907
– – ﹤0.01% 3876
2023
Q2 		$1.33M Hold
19,907
– – ﹤0.01% 3806
2023
Q1 		$855K Hold
19,907
– – ﹤0.01% 3971
2022
Q4 		$620K Buy
19,907
+11
+0.1% +$511 ﹤0.01% 4043
2022
Q3 		$1.16M Hold
19,896
– – ﹤0.01% 3956
2022
Q2 		$1.55M Hold
19,896
– – ﹤0.01% 3925
2022
Q1 		$2.11M Sell
19,896
-127
-0.6% -$10.9K ﹤0.01% 3936
2021
Q4 		$1.84M Sell
20,023
-26
-0.1% -$4.02K ﹤0.01% 4074
2021
Q3 		$4.05M Buy
20,049
+98
+0.5% +$19.8K ﹤0.01% 3785
2021
Q2 		$4.29M Buy
19,951
+668
+3% +$143K ﹤0.01% 3673
2021
Q1 		$4.37M Buy
19,283
+13,556
+237% +$3.06M ﹤0.01% 3599
2020
Q4 		$1.02M Buy
5,727
+1,673
+41% +$335K ﹤0.01% 3821
2020
Q3 		$870K Buy
4,054
+362
+10% +$90.4K ﹤0.01% 3684
2020
Q2 		$915K Buy
3,692
+2,825
+326% +$686K ﹤0.01% 3635
2020
Q1 		$222K Buy
+867
New +$136K ﹤0.01% 3850
2019
Q2 		– Sell
-82
Closed -$58K – 4243
2019
Q1 		$58K Sell
82
-19
-19% -$16.9K ﹤0.01% 4052
2018
Q4 		$80K Sell
101
-8
-7% -$7.34K ﹤0.01% 4024
2018
Q3 		$110K Buy
109
+3
+3% +$3.66K ﹤0.01% 4063
2018
Q2 		$150K Buy
106
+3
+3% +$4.39K ﹤0.01% 4012
2018
Q1 		$178K Buy
103
+36
+54% +$75.2K ﹤0.01% 3969
2017
Q4 		$102K Sell
67
-43
-39% -$61.8K ﹤0.01% 3991
2017
Q3 		$156K Buy
110
+7
+7% +$12.3K ﹤0.01% 3949
2017
Q2 		$227K Hold
103
– – ﹤0.01% 3879
2017
Q1 		$246K Buy
103
+5
+5% +$12.8K ﹤0.01% 3870
2016
Q4 		$296K Sell
98
-8
-8% -$32.2K ﹤0.01% 3828
2016
Q3 		$581K Buy
106
+3
+3% +$21.1K ﹤0.01% 3726
2016
Q2 		$624K Hold
103
– – ﹤0.01% 3742
2016
Q1 		$720K Sell
103
-1
-1% -$6.4K ﹤0.01% 3691
2015
Q4 		$443K Sell
104
-2
-2% -$13.6K ﹤0.01% 3863
2015
Q3 		$953K Hold
106
– – ﹤0.01% 3646
2015
Q2 		$1.15M Buy
106
+6
+6% +$74.3K ﹤0.01% 3624
2015
Q1 		$1.21M Buy
100
+2
+2% +$25K ﹤0.01% 3583
2014
Q4 		$1.29M Buy
98
+2
+2% +$29.8K ﹤0.01% 3442
2014
Q3 		$1.62M Buy
96
+6
+7% +$92.3K ﹤0.01% 3349
2014
Q2 		$1.48M Buy
90
+4
+5% +$71.6K ﹤0.01% 3372
2014
Q1 		$1.8M Buy
86
+19
+28% +$402K ﹤0.01% 3265
2013
Q4 		$938K Sell
67
-2
-3% -$24.2K ﹤0.01% 3435
2013
Q3 		$856K Hold
69
– – ﹤0.01% 3415
2013
Q2 		$811K Buy
+69
New +$823K ﹤0.01% 3362

Other funds holding AIM

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CB
Community Bank Dewitt, New York $840M AUM 22.23% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HI
Hoey Investments Coatesville, Pennsylvania $693M AUM 34.99% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Vanguard Group's AIM Position: Q4 2025 in Review

Vanguard Group held its AIM ImmunoTech (AIM) position steady in Q4 2025 at 17,520 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4308.

Vanguard Group first reported a position in AIM in Q2 2013 and has held it in 47 quarters since. The position peaked at $4.37M in Q1 2021. 13 funds tracked by Wall St. Rank hold AIM as of Q4 2025.

  • Vanguard Group held 17,520 shares of AIM ImmunoTech worth $19.8K as of Q4 2025.
  • Vanguard Group left its AIM ImmunoTech share count unchanged in Q4 2025.
  • AIM ImmunoTech made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4308 holding.
  • Vanguard Group first reported a position in AIM ImmunoTech in Q2 2013 and has held it in 47 quarters since.
  • Vanguard Group's AIM ImmunoTech position peaked at $4.37M in Q1 2021.
  • 13 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.